Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

Abrisqueta, P; Loscertales, J; Terol, MJ; Payer, AR; Ortiz, M; Perez, I; Cuellar-Garcia, C; de la Mata, MF; Rodriguez, A; Lario, A; Delgado, J; Godoy, A; Perez, JMA; Berruezo, MJ; Oliveira, A; Hernandez-Rivas, JA; Malo, MDG; Medina, A; Martin, PG; Osorio, S; Baltasar, P; Fernandez-Zarzoso, M; Marco, F; Mancenido, MJV; Simonovich, AS; Rubio, ML; Jarque, I; Suarez, A; Alvarez, RF; Anchel, AL; Rios, E; Castillo, MDL; Persona, EP; Munoz, RG; Ramos, R; Yanez, L; Bello, JL; Loriente, C; Acha, D; Villanueva, M – 2021